Compare ALEMBIC PHARMA with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA FRESENIUS KABI ONCO. ALEMBIC PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 16.4 22.1 74.1% View Chart
P/BV x 6.5 3.1 209.5% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALEMBIC PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
FRESENIUS KABI ONCO.
Mar-13
ALEMBIC PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs664176 377.3%   
Low Rs41279 525.4%   
Sales per share (Unadj.) Rs208.737.7 553.8%  
Earnings per share (Unadj.) Rs31.05.1 608.6%  
Cash flow per share (Unadj.) Rs37.16.7 552.0%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.242.5 339.0%  
Shares outstanding (eoy) m188.52158.23 119.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.4 76.4%   
Avg P/E ratio x17.425.0 69.5%  
P/CF ratio (eoy) x14.518.9 76.6%  
Price / Book Value ratio x3.73.0 124.8%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,46120,135 503.9%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m7,467703 1,061.8%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m39,3475,963 659.8%  
Other income Rs m9418 521.1%   
Total revenues Rs m39,4415,981 659.4%   
Gross profit Rs m8,7361,430 610.9%  
Depreciation Rs m1,152258 446.8%   
Interest Rs m184-26 -708.1%   
Profit before tax Rs m7,4931,216 616.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,568342 458.1%   
Profit after tax Rs m5,844806 725.1%  
Gross profit margin %22.224.0 92.6%  
Effective tax rate %20.928.1 74.3%   
Net profit margin %14.913.5 109.9%  
BALANCE SHEET DATA
Current assets Rs m19,5775,102 383.7%   
Current liabilities Rs m14,8962,385 624.5%   
Net working cap to sales %11.945.6 26.1%  
Current ratio x1.32.1 61.5%  
Inventory Days Days90150 59.8%  
Debtors Days Days45113 40.0%  
Net fixed assets Rs m27,0975,148 526.3%   
Share capital Rs m377158 238.3%   
"Free" reserves Rs m26,8116,556 409.0%   
Net worth Rs m27,1886,732 403.9%   
Long term debt Rs m4,993952 524.4%   
Total assets Rs m47,77810,388 459.9%  
Interest coverage x41.7-45.8 -91.1%   
Debt to equity ratio x0.20.1 129.8%  
Sales to assets ratio x0.80.6 143.5%   
Return on assets %12.67.5 168.0%  
Return on equity %21.512.0 179.5%  
Return on capital %23.614.6 161.6%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m19,4535,298 367.2%   
Fx outflow Rs m6,0651,772 342.2%   
Net fx Rs m13,3883,525 379.8%   
CASH FLOW
From Operations Rs m8,1201,274 637.3%  
From Investments Rs m-7,556-1,204 627.5%  
From Financial Activity Rs m590-196 -301.1%  
Net Cashflow Rs m1,153-126 -913.1%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 2.9 0.3 966.7%  
FIIs % 9.1 9.6 94.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 9.1 152.7%  
Shareholders   49,328 42,599 115.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  TORRENT PHARMA  VENUS REMEDIES  CIPLA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


May 6, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS